changing standards of care for use of cdk4 and 6 inhibitors in the treatment of breast cancer
Published 4 years ago • 558 plays • Length 1:17:18Download video MP4
Download video MP3
Similar videos
-
1:09:24
raising the bar in hr /her2- early breast cancer: cdk4 and 6 inhibitors
-
58:22
adjuvant cdk4 and 6 inhibition to prevent recurrences in high-risk hr /her2- early breast cancer
-
1:02:43
realizing the potential of cdk 4/6 inhibitor therapy in breast cancer: real-world data and evidence
-
7:40
cdk4/6 inhibitors in the first-line treatment setting
-
54:02
navigating shifts in the treatment landscape for metastatic her2-positive breast cancer
-
0:59
your preference for cdk4/6 inhibitor for metastatic hr breast cancer?
-
0:45
nancy lin, md, explores the role of cdk4/6 inhibitors in metastatic breast cancer management
-
1:11
unmet needs in the use of cdk4/6 inhibitors in early-stage hr /her2- breast cancer
-
57:18
navigating the expanding treatment arsenal for er /her2- breast cancer
-
8:55
cdk4/6 inhibitors in hr metastatic breast cancer
-
4:54
monarch 3 study: cdk4/6 inhibitors in the treatment of metastatic breast cancer
-
3:33
cdk 4/6 inhibitors in metastatic breast cancer
-
18:07
emerging evidence on the role of cdk4/6 inhibitors in early bc
-
21:47
esmo daily reporter talk: the role of cdk4/6 inhibitors in the early stage of #breastcancer.
-
48:13
empowering changes and revolutionizing treatment and equity in breast cancer
-
5:32
esmo 2020 expert video report on cdk4 6i in the adjuvant treatment of breast cancer
-
1:08
overcoming resistance to cdk4/6 inhibitors in er breast cancer via ctdna
-
21:08
interactive case: choosing and using cdk4/6 inhibitors in breast cancer - second-line therapy
-
4:50
expert report on tackling resistance to cdk4/6 inhibitors in er /her2-metastatic breast cancer